Follicular lymphoma: 2015 update on diagnosis and management.

about

Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.A centrocyte blood count of a quarter million.

P2860

Q39381251-9316BFEE-18D0-475B-887B-03445888F77B Q48181715-C198F326-CF19-4A4F-8DA8-AF524A20829D

P2860

Follicular lymphoma: 2015 update on diagnosis and management.

Item

http://www.wikidata.org/entity/Q40122693

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Follicular lymphoma: 2015 update on diagnosis and management.

@en

type

Item

label

Follicular lymphoma: 2015 update on diagnosis and management.

@en

prefLabel

Follicular lymphoma: 2015 update on diagnosis and management.

@en

P1476

Follicular lymphoma: 2015 update on diagnosis and management.

@en

P2093

Arnold Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

P304

1171-1178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24200

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26769125

http://www.w3.org/2001/XMLSchema#string

Follicular lymphoma: 2015 update on diagnosis and management.

about

P2860

P2860

Follicular lymphoma: 2015 update on diagnosis and management.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698